Policy & Regulation
Velicept Therapeutics Raises an Additional USD 15m in series B Round, Initiates Phase 2b Study, Receives Issuance of US Patent
17 October 2018 - - US-based pharmaceutical company Velicept Therapeutics has closed on the expansion of a series B financing bringing an additional USD 15m to support completion of the two ongoing Phase 2b studies, as well as Phase 3 enabling work, the company said.

The financing led by Samsara BioCapital, included existing investors CDK Associates, LLC; Fountain Healthcare Partners Fund II, L.P.; Longitude Venture Partners II, L.P; and founding investor Becker Ventures.

Cory Freedland, a Principal with Samsara BioCapital, has joined the company's board of directors.

Velicept also announced that VEL2001, the second of two Phase 2b clinical studies designed to evaluate two doses of a novel once daily time-dependent release formulation of solabegron in patients with overactive bladder, was initiated in July with enrollment progressing to plan.

The primary objective of the study is to evaluate the mean change in number of micturitions per day as measured by patients in an e-diary. The formulation was engineered to optimise efficacy in a convenient once daily dose.

Together with the BID study currently underway (VEL2002), the comprehensive Phase 2 program will explore the full dose range for solabegron with the goal of delivering best in class efficacy in the treatment of OAB.

The multicenter, randomised, double-blind, vehicle-controlled Phase 2b study will enroll 375 adult women ages 18 to 80 with signs and symptoms of overactive bladder from 90 centers across North America.

Patients will receive either low or high dose of solabegron once daily or placebo for 12 weeks.
Additionally, the United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,065,922 with 126 claims, directed to solid solabegron zwitterion.

The patent will expire February 23, 2037, inclusive of patent term adjustment.

This issued US Patent is part of an intellectual property portfolio, which includes other issued patents, and numerous patent applications in the US and major international markets directed to solabegron for the treatment of OAB.

Solabegron is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.

A Phase 2 study of solabegron in OAB, previously conducted by GlaxoSmithKline, evaluated a twice-daily dose in 258 patients with moderate to severe incontinence experiencing an average of 4.5 wet episodes per day.

Results demonstrated a statistically significant improvement with solabegron as compared to placebo. Furthermore, the Phase 2 study also indicated a safety and tolerability profile for solabegron that was similar to placebo.

Velicept Therapeutics is a privately held, clinical stage pharmaceutical company focused on advancing best-in-class compounds for the treatment of urological and gastrointestinal disorders.

Its lead product, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.
Login
Username:

Password: